This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 6 for:    mazindol

A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 (AMAZE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05914194
Recruitment Status : Not yet recruiting
First Posted : June 22, 2023
Last Update Posted : November 13, 2023
Sponsor:
Information provided by (Responsible Party):
NLS Pharmaceutics

Brief Summary:

The goal of this clinical trial is to see how NLS-2 (mazindol extended-release) works on symptoms of narcolepsy, including cataplexy and excessive daytime sleepiness.

Approximately 48 participants will take part in the study across the United States.

The study treatment (NLS-2 or placebo) will be administered for 8 weeks. After this treatment period, the participant may have the option to participate in a separate long-term extension study during which all participants will be treated with NLS-2.


Condition or disease Intervention/treatment Phase
Narcolepsy Type 1 Narcolepsy With Cataplexy Drug: NLS-2 Drug: Placebo Phase 3

Detailed Description:

This is a Phase 3, double-blind, placebo-controlled, multicenter, randomized, parallel-group clinical trial. The primary goal of this study is to assess the efficacy and safety of NLS-2 (mazindol extended-release) tablets in treating Narcolepsy Type 1. The trial aims to determine the effects of NLS-2 on the improvement of narcolepsy symptoms, including cataplexy frequency and excessive daytime sleepiness.

Participants in this trial will receive either NLS-2 or a placebo for 8 weeks. The treatment assignment will be concealed from both the participant and the investigator throughout the trial (unless there is an urgent medical need).

Approximately 48 patients will be enrolled at multiple clinical sites across the United States. Following the completion of the trial, participants may be given the option to enroll in a separate long-term extension trial where all participants will receive NLS-2 treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Double-Blind, Placebo-Controlled
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of NLS-2 (Mazindol Extended-Release) Tablets in the Treatment of Narcolepsy Type 1
Estimated Study Start Date : January 15, 2024
Estimated Primary Completion Date : January 15, 2025
Estimated Study Completion Date : February 15, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NLS-2
Participants will receive a single NLS-2 tablet orally once daily from Day 1 to Day 56 (until the end of Week 8).
Drug: NLS-2
Participants will receive NLS-2 tablets orally.
Other Name: mazindol extended-release (ER), mazindol controlled-release (CR)

Placebo Comparator: Placebo
Participants will receive a single NLS-2 placebo matching tablet orally once daily from Day 1 to Day 56 (until the end of Week 8).
Drug: Placebo
Participants will receive NLS-2 matching placebo tablets orally.




Primary Outcome Measures :
  1. Number of cataplexy episodes at Week 8 [ Time Frame: 8 weeks ]
    Cataplexy episodes is a clinical outcome measure that assesses the frequency of cataplexy episodes.


Secondary Outcome Measures :
  1. Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI): change from baseline [ Time Frame: 8 weeks ]
    The Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) scale consists of 8 items to evaluate daytime consequences of functioning on a 5-point Likert scale ranging from 1 to 5. The PROMIS-SRI measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. Each question has five response options ranging in value from 1 to 5. To find the total raw score with all questions answered, sum the values of the response to each question and total score ranges from 8 to 40. Higher scores indicates greater sleep impairment.

  2. Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD): change from baseline [ Time Frame: 8 weeks ]
    The Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) consists of a static 8-item questionnaire. Using a recall period of the past 7 days, it assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Each question has 5 response options ranging in value from 1 to 5. To find the total raw score with all questions answered, sum the values of the response to each question and a total score ranges from 8 to 40. Lower scores indicate less sleep disturbance. Negative changes in scores indicate improvement.

  3. Epworth Sleepiness Scale (ESS): change from baseline [ Time Frame: 8 weeks ]
    The Epworth Sleepiness Scale (ESS) is a patient-reported outcome measure that assesses daytime sleepiness. It asks the participant to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep in 8 different situations or activities that are commonly met in daily life. The total ESS score, ranging from 0 to 24, is the sum of 8 item scores, with higher scores indicating greater daytime sleepiness.

  4. Patient Global Impression of Severity (PGI-S): change from baseline [ Time Frame: 8 weeks ]
    The Patient Global Impression of Severity (PGI-S) is a patient-reported outcome measure that assesses the participant's perception of the severity of their illness. The participant rates their condition on a point scale, from "no symptoms" to "extremely severe."

  5. Clinician Global Impression of Severity (CGI-S): change from baseline [ Time Frame: 8 weeks ]
    The Clinical Global Impressions of Severity (CGI-S) is a clinician-rated outcome measure that assesses the clinician's impression of the participant's current illness severity. The clinician rates the severity of the participant's condition on a point scale, from "normal, not at all ill" to "among the most extremely ill patients".



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Adults ≥ 18 years of age at the time of signing the informed consent.
  • Documented primary diagnosis of Narcolepsy Type 1 (NT1) according to the International Classification of Sleep Disorders-Third Edition (ICSD-3) criteria.
  • Willing and able to safely discontinue all prohibited medications, including medications for the treatment of narcolepsy.
  • Body Mass Index (BMI) within the range of 18 - 40 kg/m2 (inclusive).

Key Exclusion Criteria:

  • Any other (besides narcolepsy) clinically relevant medical, behavioral, or psychiatric disorder that is associated with excessive daytime sleepiness or cataplexy.
  • History of myocardial infarction or significant cardiovascular disease, structural cardiac abnormalities, cardiomyopathy, congestive heart failure, cardiac arrhythmias, coronary artery disease, cerebrovascular disease (transient ischemic attack or stroke), or any other significant cardiac problem.
  • History of long QT Syndrome or Torsades de Pointes, or an immediate family history of sudden cardiac death.
  • History of pulmonary hypertension and/or valvulopathy.
  • History of epilepsy, convulsions, or seizures (excluding early childhood febrile seizures).
  • Significant history of head injury or head trauma.
  • Recent or active suicidal ideation or behavior
  • Current, or within the past year, diagnosis of substance abuse or dependence disorder (SUD) including alcohol abuse.
  • Narrow-angle glaucoma.
  • Severe renal or hepatic insufficiency.
  • Occupation that requires variable or nighttime shift work.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05914194


Contacts
Layout table for location contacts
Contact: Jeff Bernier 617-905-2282 amaze@nls-pharma.com

Sponsors and Collaborators
NLS Pharmaceutics
Investigators
Layout table for investigator information
Study Chair: George Apostol, MD, MS NLS Pharmaceutics
Study Director: Jennifer Franco NLS Pharmaceutics
Layout table for additonal information
Responsible Party: NLS Pharmaceutics
ClinicalTrials.gov Identifier: NCT05914194    
Other Study ID Numbers: NLS-1031
First Posted: June 22, 2023    Key Record Dates
Last Update Posted: November 13, 2023
Last Verified: June 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NLS Pharmaceutics:
Narcolepsy
Cataplexy
Narcolepsy Type 1
Narcolepsy with Cataplexy
Additional relevant MeSH terms:
Layout table for MeSH terms
Mazindol
Narcolepsy
Cataplexy
Disorders of Excessive Somnolence
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
Central Nervous System Stimulants
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Dopamine Uptake Inhibitors
Dopamine Agents